Cargando…
Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma
We report the case of a patient who was referred to our institution with a diagnosis of CD4+ small/medium-sized pleomorphic lymphoma. At the time, the patient showed a plethora of lesions mainly localizing to the legs; thus, we undertook studies to investigate the lineage and immunophenotype of the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953132/ https://www.ncbi.nlm.nih.gov/pubmed/36831170 http://dx.doi.org/10.3390/biomedicines11020634 |
_version_ | 1784893802269376512 |
---|---|
author | Petrogiannis-Haliotis, Tina Pehr, Kevin Roberge, David Rys, Ryan N. Monczak, Yury Popradi, Gizelle Ajjamada, Lissa Benlimame, Naciba Querfeld, Christiane Johnson, Nathalie Knecht, Hans |
author_facet | Petrogiannis-Haliotis, Tina Pehr, Kevin Roberge, David Rys, Ryan N. Monczak, Yury Popradi, Gizelle Ajjamada, Lissa Benlimame, Naciba Querfeld, Christiane Johnson, Nathalie Knecht, Hans |
author_sort | Petrogiannis-Haliotis, Tina |
collection | PubMed |
description | We report the case of a patient who was referred to our institution with a diagnosis of CD4+ small/medium-sized pleomorphic lymphoma. At the time, the patient showed a plethora of lesions mainly localizing to the legs; thus, we undertook studies to investigate the lineage and immunophenotype of the neoplastic clone. Immunohistochemistry (IHC) showed marked CD4 and CD8 positivity. Flow cytometry (FCM) showed two distinct T-cell populations, CD4+ and CD8+ (+/− PD1), with no CD4/CD8 co-expression and no loss of panT-cell markers in either T-cell subset. FCM, accompanied by cell-sorting (CS), permitted the physical separation of four populations, as follows: CD4+/PD1−, CD4+/PD1+, CD8+/PD1− and CD8+/PD1+. TCR gene rearrangement studies on each of the four populations (by next generation sequencing, NGS) showed that the neoplastic population was of T-cytotoxic cell lineage. IHC showed the CD8+ population to be TIA-1+, but perforin- and granzyme-negative. Moreover, histiocytic markers did not render the peculiar staining pattern, which is characteristic of acral CD8+ T-cell lymphoma (PCACD8). Compared to the entities described in the 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, we found that the indolent lymphoma described herein differed from all of them. We submit that this case represents a hitherto-undescribed type of CTCL. |
format | Online Article Text |
id | pubmed-9953132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99531322023-02-25 Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma Petrogiannis-Haliotis, Tina Pehr, Kevin Roberge, David Rys, Ryan N. Monczak, Yury Popradi, Gizelle Ajjamada, Lissa Benlimame, Naciba Querfeld, Christiane Johnson, Nathalie Knecht, Hans Biomedicines Case Report We report the case of a patient who was referred to our institution with a diagnosis of CD4+ small/medium-sized pleomorphic lymphoma. At the time, the patient showed a plethora of lesions mainly localizing to the legs; thus, we undertook studies to investigate the lineage and immunophenotype of the neoplastic clone. Immunohistochemistry (IHC) showed marked CD4 and CD8 positivity. Flow cytometry (FCM) showed two distinct T-cell populations, CD4+ and CD8+ (+/− PD1), with no CD4/CD8 co-expression and no loss of panT-cell markers in either T-cell subset. FCM, accompanied by cell-sorting (CS), permitted the physical separation of four populations, as follows: CD4+/PD1−, CD4+/PD1+, CD8+/PD1− and CD8+/PD1+. TCR gene rearrangement studies on each of the four populations (by next generation sequencing, NGS) showed that the neoplastic population was of T-cytotoxic cell lineage. IHC showed the CD8+ population to be TIA-1+, but perforin- and granzyme-negative. Moreover, histiocytic markers did not render the peculiar staining pattern, which is characteristic of acral CD8+ T-cell lymphoma (PCACD8). Compared to the entities described in the 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, we found that the indolent lymphoma described herein differed from all of them. We submit that this case represents a hitherto-undescribed type of CTCL. MDPI 2023-02-20 /pmc/articles/PMC9953132/ /pubmed/36831170 http://dx.doi.org/10.3390/biomedicines11020634 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Petrogiannis-Haliotis, Tina Pehr, Kevin Roberge, David Rys, Ryan N. Monczak, Yury Popradi, Gizelle Ajjamada, Lissa Benlimame, Naciba Querfeld, Christiane Johnson, Nathalie Knecht, Hans Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma |
title | Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma |
title_full | Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma |
title_fullStr | Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma |
title_full_unstemmed | Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma |
title_short | Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma |
title_sort | primary cutaneous multifocal indolent cd8+ t-cell lymphoma: a novel primary cutaneous cd8+ t-cell lymphoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953132/ https://www.ncbi.nlm.nih.gov/pubmed/36831170 http://dx.doi.org/10.3390/biomedicines11020634 |
work_keys_str_mv | AT petrogiannishaliotistina primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT pehrkevin primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT robergedavid primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT rysryann primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT monczakyury primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT popradigizelle primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT ajjamadalissa primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT benlimamenaciba primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT querfeldchristiane primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT johnsonnathalie primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma AT knechthans primarycutaneousmultifocalindolentcd8tcelllymphomaanovelprimarycutaneouscd8tcelllymphoma |